Romulus K. Brazzell - Oct 22, 2025 Form 4 Insider Report for KALA BIO, Inc. (KALA)

Role: Head of Research and Development and Chief Medical Officer
Signature: /s/ Mary Reumuth, Attorney-in-Fact
Stock symbol: KALA
Transactions as of: Oct 22, 2025
Transactions value $: -$38,801
Form type: 4
Date filed: 10/24/2025, 08:00 PM
Previous filing: Jun 26, 2025
SEC: View on sec.gov

Reporting Owners (1)

Name	Relationship	Address	Signature	Signature date	CIK
Brazzell Romulus K	Head of Research and Development and Chief Medical Officer	C/O KALA BIO, INC., 1167 MASSACHUSETTS AVENUE, ARLINGTON	/s/ Mary Reumuth, Attorney-in-Fact	2025-10-24	0001298079

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	KALA	Common Stock	Sale	-$38.8K	-46.7K	-56.53%	$0.83	36K	Oct 22, 2025	Direct	F1, F2

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $0.82 to $0.85, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote to this Form 4.
F2	Includes 35,952 unvested RSUs.

Content

The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $0.82 to $0.85, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote to this Form 4.

Includes 35,952 unvested RSUs.

Remarks:

Head of Research and Development and Chief Medical Officer